drugset / Trial / NCT00815594
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
Timeline
- Start
- 2008-12
- Primary completion
- 2009-03
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Subcutaneous |